Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment
Press Release Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment 102 patients randomized as of April 22, 2021, out of a target of 200 Milestone shows trial remains on track for top-line results in Q4 2021 April 23, 2021– release …